Breast Cancer Patients in Germany Now have Insurance Coverage for MammaPrintยฎ Testing through Techniker Krankenkasse
PRESS RELEASE Breast Cancer Patients in Germany Now have Insurance Read More
PROMIS study findings presented at SABCS 2019
PRESS RELEASE New Data Compare Genomic Profiling Results for Premenopausal Read More
Agendia to Present New Data at SABCS 2019 Demonstrating How Comprehensive Genomic Profiling Benefits Early-Stage Breast Cancer Patients
PRESS RELEASE Data evaluating MammaPrintยฎ and BluePrintยฎ includes new risk Read More
Agendia Presents New Data on the Biological Characteristics of Patients within Extreme Low Risk and High Risk MammaPrint Subgroups at the European Society for Medical Oncology (ESMO)
ย PRESS RELEASE IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS โ Read More
Agendia Announces Publication of Study Validating Use of MammaPrint and BluePrint Molecular Diagnostics using Targeted RNA Next-Generation Sequencing Technology
ย PRESS RELEASE IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS โ Read More
BluePrintยฎ Identifies Genomic Subtypes for African-American Breast Cancer Patients with Low Risk Outcomes
PRESS RELEASE New data presented at ASCO underscores importance of Read More
Agendia Appoints Two Industry Veterans to Board of Directors
PRESS RELEASE IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS โ 31 Read More
Agendia and Imegen Announce an Exclusive Distribution Agreement for MammaPrintยฎ and BluePrintยฎ in Spain and Portugal
PRESS RELEASE IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS โ 21 Read More
New Data Show BluePrintยฎ Identifies Estrogen Receptor Positive Breast Cancer Patients With Poor Response To Anti-Estrogen Therapy Who May Benefit From Neoadjuvant Chemotherapy
PRESS RELEASE ER+ breast cancer patients reclassified as ER+ basal-type Read More
Agendia Announces Creation of New Center of Innovation and R&D Excellence
PRESS RELEASE Simultaneous creation of Global Lab Center of Excellence Read More
